203 related articles for article (PubMed ID: 35180408)
1. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
Parker EPK; Desai S; Marti M; Nohynek H; Kaslow DC; Kochhar S; O'Brien KL; Hombach J; Wilder-Smith A
Lancet Glob Health; 2022 Mar; 10(3):e326-e328. PubMed ID: 35180408
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future.
Winthrop KL; Whitley RJ; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1249-1251. PubMed ID: 34518198
[No Abstract] [Full Text] [Related]
3. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
Spiera R; Jinich S; Jannat-Khah D
Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
[No Abstract] [Full Text] [Related]
4. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
[No Abstract] [Full Text] [Related]
5. Common Variable Immunodeficiency Disorders as a Model for Assessing COVID-19 Vaccine Responses in Immunocompromised Patients.
Ameratunga R; Woon ST; Steele R; Lehnert K; Leung E; Edwards ESJ; Brooks AES
Front Immunol; 2021; 12():798389. PubMed ID: 35116031
[No Abstract] [Full Text] [Related]
6. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
Embi PJ; Levy ME; Naleway AL; Patel P; Gaglani M; Natarajan K; Dascomb K; Ong TC; Klein NP; Liao IC; Grannis SJ; Han J; Stenehjem E; Dunne MM; Lewis N; Irving SA; Rao S; McEvoy C; Bozio CH; Murthy K; Dixon BE; Grisel N; Yang DH; Goddard K; Kharbanda AB; Reynolds S; Raiyani C; Fadel WF; Arndorfer J; Rowley EA; Fireman B; Ferdinands J; Valvi NR; Ball SW; Zerbo O; Griggs EP; Mitchell PK; Porter RM; Kiduko SA; Blanton L; Zhuang Y; Steffens A; Reese SE; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron MA; Thompson MG; DeSilva MB
MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1553-1559. PubMed ID: 34735426
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccination in immunocompromised patients.
Sonani B; Aslam F; Goyal A; Patel J; Bansal P
Clin Rheumatol; 2021 Feb; 40(2):797-798. PubMed ID: 33426632
[No Abstract] [Full Text] [Related]
8. COVID-19 in Immunocompromised Patients: A Systematic Review.
Stainer A; Amati F; Suigo G; Simonetta E; Gramegna A; Voza A; Aliberti S
Semin Respir Crit Care Med; 2021 Dec; 42(6):839-858. PubMed ID: 34918325
[TBL] [Abstract][Full Text] [Related]
9. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
[No Abstract] [Full Text] [Related]
10. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
[No Abstract] [Full Text] [Related]
11. Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.
Golding B; Lee Y; Golding H; Khurana S
Ann Rheum Dis; 2021 Oct; 80(10):1359-1361. PubMed ID: 34272252
[No Abstract] [Full Text] [Related]
12. SARS-COV-2 vaccination after stem cell transplantation for scleroderma.
Rimar D; Slobodin G; Paz A; Henig I; Zuckerman T
Ann Rheum Dis; 2021 Oct; 80(10):1354-1355. PubMed ID: 34049853
[No Abstract] [Full Text] [Related]
13. Vaccine against SARS-CoV-2 in previously infected health care workers.
Parisi SG
EBioMedicine; 2021 Sep; 71():103556. PubMed ID: 34454402
[No Abstract] [Full Text] [Related]
14. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 vaccines for patients with haematological conditions.
Sun C; Pleyer C; Wiestner A
Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822
[No Abstract] [Full Text] [Related]
16. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration.
Yi SG; Knight RJ; Graviss EA; Moore LW; Nguyen DT; Ghobrial RM; Gaber AO; Huang HJ
Transplantation; 2021 Jul; 105(7):e72-e73. PubMed ID: 33741844
[No Abstract] [Full Text] [Related]
17. SARS-CoV-2 infection confers greater immunity than shots.
Wadman M
Science; 2021 Sep; 373(6559):1067-1068. PubMed ID: 34516858
[No Abstract] [Full Text] [Related]
18. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
Albach FN; Burmester GR; Biesen R
Ann Rheum Dis; 2021 Oct; 80(10):1361-1362. PubMed ID: 34167947
[No Abstract] [Full Text] [Related]
19. Being fair to participants in placebo-controlled COVID-19 vaccine trials.
Dal-Ré R; Orenstein W; Caplan AL
Nat Med; 2021 Jun; 27(6):938. PubMed ID: 33903751
[No Abstract] [Full Text] [Related]
20. Special focus 'SARS-CoV-2 / COVID-19: advances in developing vaccines and immunotherapeutics'.
Dhama K; Singh Malik Y; Rabaan AA; Rodriguez-Morales AJ
Hum Vaccin Immunother; 2020 Dec; 16(12):2888-2890. PubMed ID: 33393853
[No Abstract] [Full Text] [Related]
[Next] [New Search]
